Published in Law and Health Weekly, January 20th, 2007
This award is given by the international consultancy to those companies that have stood out in innovation and in implementation of a successful business plan in an increasingly competitive worldwide market.
This award has been presented to Neuropharma due to the R&D that the company is carrying out in the therapeutic area of GSK-3 inhibitors as a new strategy to find an effective treatment for Alzheimer disease. Neuropharma's lead compound from this class, code named as NP-12, is in Phase I clinical trials. NP-12 has so far been administered in 68 subjects, and there have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.